Cesca Therapeutics Announces First Quarter 2018 Financial Results and Provides Corporate Update
May 14, 2018 16:05 ET
|
Cesca Therapeutics Inc.
RANCHO CORDOVA, Calif., May 14, 2018 (GLOBE NEWSWIRE) -- Cesca Therapeutics Inc. (NASDAQ:KOOL), a market leader in automated cell processing and point-of-care, autologous cell-based therapies, today...
Cesca Therapeutics to Announce Financial Results for the First Quarter Ended March 31, 2018 and Host Conference Call on May 14
May 09, 2018 08:30 ET
|
Cesca Therapeutics Inc.
RANCHO CORDOVA, Calif., May 09, 2018 (GLOBE NEWSWIRE) -- Cesca Therapeutics Inc. (“Cesca” or the “Company”) (NASDAQ:KOOL), a market leader in automated cell processing and point-of-care, autologous...
Cesca Therapeutics Inc. Presents New Data on its Proprietary X-Series™ Cellular Processing Systems
May 04, 2018 17:00 ET
|
Cesca Therapeutics Inc.
Two posters presented at the International Society for Cellular Therapy (ISCT)2018 Annual Meeting RANCHO CORDOVA, Calif., May 04, 2018 (GLOBE NEWSWIRE) -- Cesca Therapeutics Inc. (“Cesca” or the...
Cesca Therapeutics Inc. to Exhibit at Several Upcoming Cell Therapy Conferences
April 25, 2018 08:30 ET
|
Cesca Therapeutics Inc.
RANCHO CORDOVA, Calif., April 25, 2018 (GLOBE NEWSWIRE) -- Cesca Therapeutics Inc. (“Cesca” or the “Company”) (NASDAQ:KOOL) today announced that the Company will be exhibiting its full suite of...
Cesca Therapeutics Announces Evaluation Agreement With The University Of North Carolina Lineberger Advanced Cellular Therapeutics Facility for X-Series™ Products That Provide Automated, Closed System Cellular Processing
April 24, 2018 08:30 ET
|
Cesca Therapeutics Inc.
RANCHO CORDOVA, Calif., April 24, 2018 (GLOBE NEWSWIRE) -- Cesca Therapeutics Inc. (NASDAQ:KOOL), a market leader in automated cell processing and point-of-care, autologous cell-based therapies,...
Cesca Therapeutics Announces First Evaluation Agreement With a Leading U.S. Academic Research Institution for X-Series™ Products That Provide Automated, Closed System Cellular Processing
April 17, 2018 08:30 ET
|
Cesca Therapeutics Inc.
RANCHO CORDOVA, Calif., April 17, 2018 (GLOBE NEWSWIRE) -- Cesca Therapeutics Inc. (NASDAQ:KOOL), a market leader in automated cell processing and point-of-care, autologous cell-based therapies,...
Cesca Therapeutics Inc. Announces Release of X-Mini™ Cell Selection Kit for the CAR-T Research Market
April 03, 2018 08:30 ET
|
Cesca Therapeutics Inc.
RANCHO CORDOVA, Calif., April 03, 2018 (GLOBE NEWSWIRE) -- Cesca Therapeutics Inc. (“Cesca”) (NASDAQ:KOOL), a market leader in automated cell processing and point-of-care, autologous cell-based...
Cesca Therapeutics Inc. Announces Two Abstracts Accepted for Poster Presentation at the International Society for Cellular Therapy (ISCT) 2018 Annual Meeting
March 28, 2018 07:00 ET
|
Cesca Therapeutics Inc.
RANCHO CORDOVA, Calif., March 28, 2018 (GLOBE NEWSWIRE) -- Cesca Therapeutics Inc. (“Cesca”) (NASDAQ:KOOL) today announced that two late-breaking abstracts involving the use of Cesca’s X-Series™...
Cesca Therapeutics Announces Registered Direct Offering
March 26, 2018 09:00 ET
|
Cesca Therapeutics Inc.
RANCHO CORDOVA, Calif., March 26, 2018 (GLOBE NEWSWIRE) -- Cesca Therapeutics Inc. (Nasdaq:KOOL), a market leader in automated cell processing and point-of-care, autologous cell-based therapies,...
Cesca Therapeutics Announces Financial Results for the Transition Period July 1, 2017 to December 31, 2017, and Provides Corporate Update
March 22, 2018 16:05 ET
|
Cesca Therapeutics Inc.
RANCHO CORDOVA, Calif., March 22, 2018 (GLOBE NEWSWIRE) -- Cesca Therapeutics Inc. (NASDAQ:KOOL), a market leader in automated cell processing and point-of-care, autologous cell-based therapies,...